JCN Newswire
TOKYO and RAHWAY, N.J., Sep 17, 2024 – (JCN Newswire) – Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSDoutside of the United States and Canada) today announced results from the first interim analysis of the Phase 3 LEAP-012 trial evaluating LENVIMA (lenvatinib…
Read More
LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcin
Augustine Kazmierczak
02:34
TOKYO and RAHWAY, N.J., Sep 17, 2024 – (JCN Newswire) – Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSDoutside of the United States and Canada) today announced results from the first interim analysis of the Phase 3 LEAP-012 trial evaluating LENVIMA (lenvatinib…
